11 Mar 2015 Posted in News Release By Press Office
Paul Catchpole said:
“We welcome the announcement that the very first innovative medicine in an area of high unmet medical need has now been granted a positive scientific opinion as part of the Early Access to Medicines Scheme (EAMS) initiative.
This should mean that eligible NHS patients are now rapidly able to gain consistent access to this important new medicine far earlier than would otherwise have been the case. Delivering earlier and faster access for NHS patients to all new medicines is crucial to further improving health outcomes for patients. EAMS has a vitally important role to play in this.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811